Las acciones de Concord Biotech ganan un 6% tras la aprobación de la USFDA para las tabletas de Tofacitinib
⚡ Resumen rápido
Concord Biotech's shares surged over 6% after receiving USFDA approval for its Tofacitinib Tablets in 5 mg and 10 mg strengths. This approval for rheumatoid arthritis and other conditions is expected to bolster its U.S.